Stock Ratings / Health Care / NXTC / options

RMTI (28) RNAZ (47) BCTX (41) AARD (37) ⌘ Pro Terminal →

NextCure Inc. (NXTC) Options Positioning, Max Pain & Unusual Sweeps

$6.53 +2.92% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

NextCure Inc. (NXTC) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $29.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NXTC)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (NXTC)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for NXTC.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NXTC)

✓Walkthrough of NXTC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NXTC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.10%📐 WEDGE COMPRESSION COIL

2026-10-30O $6.33H $6.58L $6.21C $6.53VOL 19.1K

RES: $7.41SUP: $4.58SMA50: $6.10SMA200: $7.85

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NXTC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NXTC Butterfly Map → + Track NXTC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NXTC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NXTC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NXTC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NXTC)

Health Care Rank #389 of 1016 ⚔️ RMTI vs NXTC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NXTC vs. RMTI, RNAZ, BCTX, AARD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NextCure Inc. (NXTC) ranks #389 by composite RQD confidence (48/100, grade D) and #805 by equity capitalization ($29.9M). Within this direct 5-issuer industry benchmark cohort, NXTC leads on earnings valuation at N/A trailing P/E, while RMTI leads on capital efficiency and profitability with -10.6% ROIC and 16.9% gross margin. NXTC currently leads its immediate peer cohort in composite quantitative strength at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NXTC ACTIVE NextCure Inc.	D	48/100	—	—	-35.0%	+2.92%	$29.9M	Benchmark Subject
RMTI Rockwell Medical Inc.	E	28/100	—	16.9%	-10.6%	0.00%	$29.5M	/rmti-vs-nxtc →
RNAZ TransCode Therapeutics Inc.	D	47/100	—	—	-35.0%	-0.57%	$29.3M	/rnaz-vs-nxtc →
BCTX BriaCell Therapeutics Corp.	D-	41/100	—	—	—	-5.43%	$28.9M	/bctx-vs-nxtc →
AARD Aardvark Therapeutics Inc.	D-	37/100	—	—	-35.0%	-4.64%	$31.5M	/aard-vs-nxtc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001661059

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NextCure Inc. (NXTC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$55.8M, operating cash flow of -$49.6M, and free cash flow of -$49.6M (-20.2% YoY). On the balance sheet, NXTC closed FY2025 with $50.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$55.8M	-$49.6M	-$49.6M	$50.2M	—
FY2024 (FY)	2024-12-31	$0	-$55.7M	-$40.8M	-$41.3M	$80.9M	—
FY2023 (FY)	2023-12-31	$0	-$62.7M	-$53.0M	-$53.0M	—	—

3. NXTC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NXTC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, NextCure Inc. (NASDAQ: NXTC) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $6.53 (+2.92% 1D, market cap $29.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NXTC ranks #389 in composite RQD confidence.

How does NXTC compare to RMTI and RNAZ in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NXTC carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RMTI (Rockwell Medical Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -10.6%, cap $29.5M) and RNAZ (TransCode Therapeutics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $29.3M). Among the 5-stock peer group, NXTC leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NXTC?

Per NXTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001661059), NextCure Inc. generated $0 in revenue, -$55.8M in net income, and -$49.6M in free cash flow against $50.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NXTC trading relative to its 50-day, 200-day, and 52-week technical levels?

NXTC last traded at $6.53 (+2.92% on volume of 58,262 shares), positioning the stock +7.05% above its 50-day simple moving average ($6.10) and -16.82% below its 200-day simple moving average ($7.85). Across its 52-week range of $1.55 to $15.74, NXTC sits at the 35.1% percentile with a 14-day RSI of 54.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.71 to $7.35).